A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

NCT03669718 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Oropharynx
HPV16 Positive

Interventions

BIOLOGICAL: ISA101b
DRUG: Cemiplimab
OTHER: Placebo

Sponsor

ISA Pharmaceuticals

Collaborators

[object Object]